-
Recent Posts
- Dementia-Friendly Communities Provision, Viewed as a Social Determinant of Health (JGCR / NHS England / WHO)
- International Perspectives on the Possible Impact of the COVID-19 Pandemic and Lockdown on Abuse of the Elderly (JGCR / American Journal of Geriatric Psychiatry / JAGS)
- Updates Relating to the Lancet Commission on Dementia Prevention, Intervention, and Care (Lancet / Alzheimer’s Research and Therapy / Alzheimer’s and Dementia)
- A Brief Review of How the COVID-19 Pandemic Relates to Elderly Care and Research (JGCR)
- Some Speculated / Potential Benefits of COVID-19 (JGCR / BBC Radio 4’s Rethink / BGS)
Archives
- September 2020
- August 2020
- June 2020
- April 2020
- March 2020
- February 2020
- January 2020
- December 2019
- November 2019
- October 2019
- September 2019
- August 2019
- July 2019
- June 2019
- May 2019
- April 2019
- March 2019
- February 2019
- January 2019
- December 2018
- November 2018
- October 2018
- September 2018
- August 2018
- July 2018
- June 2018
- May 2018
- April 2018
- March 2018
- February 2018
- January 2018
- December 2017
- November 2017
- October 2017
- September 2017
- August 2017
- July 2017
- June 2017
- May 2017
- April 2017
- March 2017
- February 2017
- January 2017
- December 2016
- November 2016
- October 2016
- September 2016
- August 2016
- July 2016
- June 2016
- May 2016
- April 2016
- March 2016
- February 2016
- January 2016
- December 2015
- November 2015
- October 2015
- September 2015
- August 2015
- July 2015
- June 2015
- May 2015
- April 2015
- March 2015
- February 2015
- January 2015
- December 2014
- November 2014
- October 2014
- September 2014
- August 2014
- July 2014
- June 2014
- May 2014
- April 2014
- March 2014
- February 2014
- January 2014
- December 2013
- November 2013
- October 2013
- September 2013
- August 2013
- July 2013
- June 2013
- May 2013
- April 2013
- March 2013
- February 2013
- January 2013
- December 2012
- November 2012
- October 2012
- September 2012
- August 2012
- July 2012
- June 2012
- May 2012
- April 2012
- March 2012
- February 2012
- January 2012
- December 2011
- November 2011
- October 2011
- September 2011
- August 2011
- July 2011
- June 2011
- May 2011
- April 2011
- March 2011
- February 2011
- January 2011
- December 2010
- November 2010
Categories
- Antipsychotics
- Assistive Technology
- Charitable Bodies
- Commissioning
- Delirium
- Depression
- Enhancing the Healing Environment
- Falls
- Falls Prevention
- Guidelines
- Hip Fractures
- Housing
- Hypertension
- In the News
- Integrated Care
- International
- Local Interest
- Mental Health
- Models of Dementia Care
- National
- ADASS
- All-Party Parliamentary Group (APPG) on Dementia
- BSI
- CQC: Care Quality Commission
- Department of Health
- Department of Health and Social Care (DHSC)
- Health Education England (HEE)
- Housing LIN
- MAGDR
- Mental Health Foundation
- Mental Health Network (NHS Confederation)
- MHP Health Mandate
- National Audit Office
- National Voices
- NEoLCIN
- NEoLCP
- NHS
- NHS Alliance
- NHS Confederation
- NHS Employers
- NHS England
- NHS Evidence
- NHS Improvement
- NICE Guidelines
- NIHR
- NIHRSDO
- Northern Ireland
- Patients Association
- Public Health England
- RCN
- Royal College of Physicians
- Royal College of Psychiatrists
- SCIE
- Scotland
- UK
- UK NSC
- Wales
- Non-Pharmacological Treatments
- Nutrition
- Pain
- Parkinson's Disease
- Patient Care Pathway
- Person-Centred Care
- Personalisation
- Pharmacological Treatments
- Proposed for Next Newsletter
- Quick Insights
- Standards
- Statistics
- Stroke
- Systematic Reviews
- Telecare
- Telehealth
- Universal Interest
Google Translate (100+ Languages)
Tag Archives: Drug Identification
A Further Set-Back for Progress in Dementia Drug Development? (BBC News)
Summary Drug company Pfizer is to cease activity in its neuroscience drug discovery programmes, which will impact on ongoing research into drugs for Alzheimer’s Disease and Parkinson’s Disease. Paradoxically the company does promise plans to create a new fund dedicated … Continue reading →
Posted in BBC News, For Researchers (mostly), In the News, International, Management of Condition, Pharmacological Treatments, Quick Insights, Universal Interest
|
Tagged Big Pharma, Dementia Research, Dementia Research Funding, Disease Modifying Treatment by 2025 (Aim), Disease-Modifying Therapies, Disease-Modifying Therapies for Dementia, Drug Discovery Programmes, Drug Identification, Drug Trials Failure Rate, Drug-Development Pipeline, Global Context, Global Outlook, International Organisations, International Programmes, Neurological Conditions, Neurological Disease, Neurological Disorders, Neuroscience Drug Discovery Programmes (Pfizer), Neuroscience Research, Pfizer, Pfizer Inc., Pharmaceutical Industry, Research and Development, Research and Innovation, Research Commitment, Research Funding
|
Leave a comment
Faintest Hints of Promise From a Recent Dementia Drug Trial? (BBC News / Alzheimer’s Association International Conference)
Summary Data from a recent trial involving 891 patients, presented at the Alzheimer’s Association International Conference in Toronto this week, indicates that an experimental new drug (LMTX) appears to slow the death of brain cells and preserve mental function in … Continue reading →
Posted in Alzheimer’s Disease International (ADI), BBC News, Charitable Bodies, For Doctors (mostly), For Nurses and Therapists (mostly), For Researchers (mostly), In the News, International, Management of Condition, Models of Dementia Care, Pharmacological Treatments, Quick Insights, Universal Interest
|
Tagged Abnormal Proteins (Tau), Alzheimer Disease and Related Disorders Research Unit of the McGill University Research Centre for Studies in Aging (Douglas Mental Health University Institute), Alzheimer's Disease Research Unit: McGill University (Canada), Alzheimer’s Association, Alzheimer’s Association International Conference® (AAIC®) 2016, BBC Health News, Degenerative Tauopathy, Dementia Research, Disease Modifying Treatment by 2025 (Aim), Disease-Modifying Therapies, Disease-Modifying Therapies for Dementia, Douglas Mental Health University Institute: McGill University Research Centre for Studies in Aging, Dr Serge Gauthier: Director of Alzheimer's Disease Research Unit at McGill University in Canada, Drug Development for Alzheimer's Disease, Drug Discovery Programmes, Drug Identification, Drug Trials, Drug Trials Failure Rate, Drug-Development Pipeline, Drugs for Treatment of Alzheimer’s Disease, Global Dementia Research, Leuco-methylthioninium-bis (hydromethanesulfonate) (LMTM), Leucomethylthioninium Salts (LMTX), LMTM Monotherapy, LMTX, Ltd., Neurodegeneration, Neurodegenerative Disease Research, Research and Development, Research and Innovation, Research Commitment, Tau, Tau Aggregation, Tau Aggregation Inhibitor Therapy, Tau Aggregation Inhibitors, Tau Pathology, Tau Tangles, Tau-Targeting Drugs, Tauopathy, TauRX, TauRx Therapeutics, Treatment and Prevention of Dementia
|
Leave a comment
European Medicines Agency Consultation on Pharmacological Treatments for Dementia (EMA)
Summary The European Medicines Agency (EMA) has released an updated draft guideline on medicines for the treatment of Alzheimer’s Disease and other types of dementia, for consultative feedback. Full Text Link Reference Consultation on revised guideline on medicines to treat … Continue reading →
Posted in Diagnosis, For Doctors (mostly), For Nurses and Therapists (mostly), For Researchers (mostly), International, Management of Condition, Mental Health, Models of Dementia Care, Pharmacological Treatments, Quick Insights, Standards
|
Tagged Accelerating Alzheimer's Research and Drug Development, Alzheimer’s Disease Biomarkers, Behavioural and Psychiatric Symptoms of Dementia, Behavioural and Psychological Symptoms of Dementia (BPSD), Biomarker Assessments in Alzheimer’s Disease, Biomarker Assessments in Alzheimer’s Disease Clinical Trials, Biomarker Assessments in Clinical Trials, Biomarker Development, Biomarkers, Biomarkers Predicting Cognitive Decline and Alzheimer's Disease, Blood Proteins as Biomarkers of Disease Research, Blood-Based Biomarkers of Pre-Symptomatic Alzheimer’s Disease, BPSD: Behavioral and Psychological Symptoms of Dementia, Cardiovascular Adverse Events, Clinical Diagnostic Criteria, Committee for Medicinal Products for Human Use (CHMP), Comparison IWG and NIA-AA Criteria for Clinical Diagnosis of Alzheimer´s Disease, Diagnostic Tests, Disease Modifying Treatment by 2025 (Aim), Disease-Modifying Therapies, Disease-Modifying Therapies for Dementia, Drug Development for Alzheimer's Disease, Drug Discovery Programmes, Drug Identification, Drug Target Validation, Drug-Development Pipeline, Drugs for Treatment of Alzheimer’s Disease, Early Detection of Preclinical Disease, Early Diagnosis, Early Diagnosis of Alzheimer's Disease, Early Diagnostic Criteria, EMA Central Nervous System Working Party, EMA: European Medicines Agency, Enrichment of Study Populations, European Medicines Agency, European Medicines Agency (EMA), Genetic Testing, Genetic Triggers, Genetics of Alzheimer's Disease, Guideline on Clinical Investigation of Medicines for Alzheimer’s Disease and Other Dementias, Guideline on Medicinal Products for the Treatment of Alzheimer’s Disease and Nine Other Dementias, International Organisations, International Programmes, International Working Group (IWG), Long-Term Efficacy and Safety Studies, Medical Research, Medicines Development, Medicines Mechanism of Action, National Institutes of Health (NIH), Neurodegeneration, Neurodegenerative Disease Research, Neurodegenerative Diseases, Neurological Adverse Events, Neurological Disorders, Novel Targets in Neurodegeneration, Ordering of Alzheimer's Disease Biomarkers, Pharmaceutical Industry, Pharmacological Research, Preclinical Alzheimer's Disease, Preclinical Biomarkers in Alzheimer's Disease, Preclinical Indicators and Dementia, Preclinical Indicators in Alzheimer's Disease, Prodromal Alzheimer's Disease, Psychiatric Adverse Events, Research and Development, Research and Innovation, Research Commitment, Research Consortia, Research Culture, Research Networks, Research Programmes, Safety and Efficacy Markers, Stratification of Subgroups (Clinical Trials), Target Discovery and Preclinical Validation, Therapeutic Target(s): Identification, Timely Diagnosis
|
Leave a comment
Dementia Discovery Fund Launched (WDC / ARUK)
Summary The Dementia Discovery Fund (DDF) was launched on October 21st 2015. Full Text Link Reference Launch of Dementia Discovery Fund. London [Online]: World Dementia Council (WDC), November 10th 2015. See also: Full Text Link Reference $100m Dementia Discovery Fund … Continue reading →
Posted in Alzheimer’s Research UK, Charitable Bodies, Commissioning, Department of Health, For Doctors (mostly), For Nurses and Therapists (mostly), For Researchers (mostly), In the News, International, Management of Condition, Mental Health, Models of Dementia Care, National, Pharmacological Treatments, Quick Insights, UK, Universal Interest
|
Tagged $100m Dementia Discovery Fund, Ageing and Dementia, Ageing and Society, Ageing Population, Alzheimer's Research UK, Alzheimer’s Research UK (ARUK), Andrew Plump: Chief Medical and Scientific Officer at Takeda Pharmaceutical Company Limited, ARUK: Alzheimer’s Research UK, Big Pharma, Biogen, Biopharmaceutical Companies, Collaboration, Collaborative Projects, Cross-Sector Partnerships, Dementia Discovery Fund, Dementia Discovery Fund (DDF), Dementia Research, Dementia Research Funding, Disease Modifying Treatment by 2025 (Aim), Disease-Modifying Therapies, Disease-Modifying Therapies for Dementia, Dr Jan Lundberg: President of Lilly Research Laboratories, Dr Matthew Norton: Alzheimer's Research UK, Drug Discovery Programmes, Drug Identification, Drug Regulation, Drug-Development Pipeline, Eli Lilly Inc., Eli Lilly’s UK Dementia Research Centre, First Global Ministerial Conference on Global Action Against Dementia, First WHO Ministerial Conference on Global Action Against Dementia, G8 Dementia Summit: Global Action Against Dementia, GlaxoSmithKline, Global Action Against Dementia, Global Action Against Dementia (GAAD), Global Ministerial Conference on Global Action Against Dementia (WHO), Global Outlook, Government Research Funding, GSK Johnson & Johnson, International Collaborations, International Programmes, Jane Ellison, Johnson & Johnson, Lilly, Mikael Dolsten: President of Worldwide Research and Development at Pfizer, Partnership, Partnership and Collaboration, Partnership Working, Patrick Vallance: President of Pharmaceuticals R&D at GSK, Paul Stoffels: Worldwide Chairman of Johnson & Johnson, Pfizer, Pfizer Inc., Pharmaceutical Industry, Research and Development, Research and Innovation, Research Commitment, Research Funding, SV Life Sciences, SV Life Sciences (SVLS), Takeda, WDC: World Dementia Council, World Dementia Council
|
Leave a comment
Challenges in Developing Disease-Modifying Treatments for Dementia (Department of Health)
Summary Raj Long, the Senior Regulatory Officer at the Bill & Melinda Gates Foundation, explores the problems in developing treatments for dementia. The independent “Finding a Path for the Cure for Dementia” report is a contribution to the G8 Dementia … Continue reading →
Posted in Charitable Bodies, Commissioning, Department of Health, For Doctors (mostly), For Nurses and Therapists (mostly), For Researchers (mostly), In the News, International, Management of Condition, Models of Dementia Care, Patient Care Pathway, Pharmacological Treatments, Quick Insights, Standards, UK, Universal Interest
|
Tagged Academia-Industry Partnerships, Academic Research, AIFA: Italian Medicines Agency, Attrition Analysis, BfArM: Federal Institute of Drugs and Medical Devices, BfArM: Federal Institute of Drugs and Medical Devices (Germany), Bill and Melinda Gates Foundation, Biopharmaceutical Companies, Burden of Dementia, Canada, CEOi: Global CEO Initiative on Alzheimer’s Disease, Challenge on Dementia (David Cameron), Charitable Funding, Clinical Trial Efficiencies, Collaboration, Collaborative Projects, Composite End Points, Consistent Global Development Pathways, Cross-Sector Partnerships, CTEG: Clinical and Technical Expert Group, Danish Health and Medicines Authority, Data Sharing, Dementia Challenge, Dementia Research, Dementia Research Funding, Dementia Research Priorities, Dementia Research: UK Impact, Denmark, Department of Health Dementia Challenge, Diagnosis and Referral, Disease Modifying Treatment by 2025 (Aim), Disease-Modifying Therapies, Disease-Modifying Therapies for Dementia, DKMA: Danish Health and Medicines Authority, Drug Discovery Programmes, Drug Identification, Drug Regulation, Drug-Development Pipeline, Eli Lilly Inc., Eli Lilly’s UK Dementia Research Centre, EMA: European Medicines Agency, European Medicines Agency, European Union, FIH: First in Humans, Financial Incentives, First Global Ministerial Conference on Global Action Against Dementia, Food and Drug Administration, G20 Countries, G7 Countries, G8 Dementia Summit: Global Action Against Dementia, G8 Summit, Gaps in the Basic Science, Germany, Global Alzheimer’s and Dementia Action Alliance (GADAA), Global Envoy for Dementia Innovation, Global Leadership, Global Outlook, Global Social Investment for Dementia, Government Research Funding, Health Canada, IAP Steering Committee, IDAP Steering Committee, IDAP: International Dementia Advisory Platform, IFPMA: International Federation of Pharmaceutical Manufacturers & Associations, Incentives and Investment, Incentives for Drug Development, Independent Safety Review Committee, Integrated Development Pathway, International Collaborations, International Dementia Advisory Platform (IDAP), International Dementia Research Inventories, International Programmes, Italian Medicines Agency, Italy, Japan, Japan: Pharmaceuticals and Medical Devices (Japan), Knowledge Translation, MEB: Medicines Evaluations Board, Medicines and Healthcare Products Regulatory Agency, Medicines Evaluation Board Netherlands, MHRA: Medicines and Healthcare Products Regulatory Agency, Modelling and Extrapolation, Multilateral Cooperation, Multilateral Regulator Cooperation, Netherlands, Neurodegeneration, Neurodegenerative Disease Research, Neurodegenerative Diseases, Neurodegenerative Disorders, Neurological Research, OHE: Office of Health Economics, Open Access Databases, Open Access Knowledge Resources, Open Access Research, Open Science, Organisation for Economic Co-operation and Development (OECD), Organisation for Economic Co-operation and Development (OECD) Countries, Organisation for Economic Cooperation and Development, Partnership, Partnership and Collaboration, Partnership Working, Patient Viewpoint, Philanthropic Funding, Pipeline Databases, PMDA: Pharmaceutical and Medicines Devices Agency, Public-Private Partnership (PPP), Quantifiable Reproducible Outcome Measures, Raj Long: Senior Regulatory Officer for Integrated Development in Global Health at the Bill & Melinda Gates Foundation, Reasons for Termination of Trials, Regulator Perspectives, Regulatory Agencies, Regulatory Experts, Research and Developers’ Status Quo, Research and Development, Research and Innovation, Research Commitment, Research Funding, Research Status Quo, Resource and Incentives, Risk Benefit Balance, Standardisation and Validation of Cognitive Endpoints, Swiss Medic, Switzerland, United States, WDC: World Dementia Council, World Dementia Council, World Health Organisation (WHO)
|
Leave a comment
Announcements From WHO’s First Ministerial Conference on Global Action Against Dementia Conference (Dementia Challenge / Department of Health / World Dementia Council / WHO / GAAD)
Summary Health Secretary Jeremy Hunt has announced a $100 million Dementia Discovery Fund at the World Health Organisation’s First Ministerial Conference on Global Action Against Dementia Conference. The Dementia Discovery Fund will be used to finance dementia research with the … Continue reading →
Posted in Acute Hospitals, Charitable Bodies, Commissioning, Community Care, Department of Health, Diagnosis, End of Life Care, For Carers (mostly), For Doctors (mostly), For Nurses and Therapists (mostly), For Researchers (mostly), For Social Workers (mostly), In the News, Integrated Care, International, Management of Condition, Mental Health, Models of Dementia Care, National, NIHR, Non-Pharmacological Treatments, Patient Care Pathway, Person-Centred Care, Pharmacological Treatments, Quick Insights, Standards, Statistics, UK, Universal Interest, World Health Organization (WHO)
|
Tagged $100m Dementia Discovery Fund, Ageing and Dementia, Ageing and Society, Ageing Population, Alzheimer's Research UK, Alzheimer’s Research UK (ARUK), ARUK: Alzheimer’s Research UK, Awareness Raising, Big Pharma, Biogen, Biopharmaceutical Companies, Burden of Dementia, Challenge on Dementia (David Cameron), Collaboration, Collaborative Projects, Cross-Sector Partnerships, Dementia Challenge, Dementia Diagnosis, Dementia Discovery Fund, Dementia Research, Disease Modifying Treatment by 2025 (Aim), Disease-Modifying Therapies, Disease-Modifying Therapies for Dementia, Dr Margaret Chan: WHO Director-General, Drug Discovery Programmes, Drug Identification, Drug Regulation, Drug-Development Pipeline, Eli Lilly Inc., Eli Lilly’s UK Dementia Research Centre, First Global Ministerial Conference on Global Action Against Dementia, First WHO Ministerial Conference on Global Action Against Dementia, Former Health Secretary Jeremy Hunt, G8 Dementia Summit: Global Action Against Dementia, GlaxoSmithKline, Global Action Against Dementia, Global Action Against Dementia (GAAD), Global Ministerial Conference on Global Action Against Dementia (WHO), Global Outlook, Government Research Funding, Human Rights, International Collaborations, International Programmes, Johnson & Johnson, JP Morgan, Knowledge Translation, Leadership, Lilly, Ms. Cathrin Petty: JP Morgan, OECD, Organisation for Economic Co-operation and Development (OECD), Organisation for Economic Co-operation and Development (OECD) Countries, Partnership, Partnership and Collaboration, Partnership Working, Pfizer, Pfizer Inc., Pharmaceutical Industry, Prime Minister’s Dementia Challenge, Quality of Care, Quality of Care and Support, Quality of Care for People With Dementia, Reducing Stigma, Research and Development, Research and Innovation, Research Commitment, Research Funding, Rt Hon Jeremy Hunt MP: Former Secretary of State for Health, WDC: World Dementia Council, World Dementia Council, World Health Organisation (WHO)
|
Leave a comment
Emerging Leaders In Dementia: Communiqué for the First WHO Ministerial Conference on Global Action Against Dementia (World Dementia Council)
Summary A group of “young leaders in dementia” will take part in the First Global Ministerial Conference on Global Action Against Dementia, which is to be hosted by the World Health Organisation (WHO) in Geneva on March 16th – 17th … Continue reading →
Posted in Acute Hospitals, Assistive Technology, Charitable Bodies, Commissioning, Community Care, Department of Health, Diagnosis, For Carers (mostly), For Doctors (mostly), For Nurses and Therapists (mostly), For Researchers (mostly), For Social Workers (mostly), In the News, Integrated Care, International, Management of Condition, Mental Health, Models of Dementia Care, Patient Care Pathway, Person-Centred Care, Pharmacological Treatments, Quick Insights, Standards, UK, Universal Interest, World Health Organization (WHO)
|
Tagged Ageing and Dementia, Ageing and Society, Ageing Population, American Association for the Advancement of Sciences, Awareness Raising, Burden of Dementia, Care Standards, Care Standards in Hospitals, Carer Experience, Carer's Experience of Dementia, Carers’ Experiences of the Dementia Journey, Center for Public Engagement with Science and Technology (the American Association for the Advancement of Sciences), Challenge on Dementia (David Cameron), Collaboration, Collaborative Projects, Cross Sector Working, Cross-Sector Partnerships, Dementia Challenge, Dementia Diagnosis, Dementia Grand Challenge Proposal (WDC or G7 Sponsorship for Jumpstarting Radical Breakthroughs in Prevention Cure and Care of Dementia)), Dementia Narrative (Qualitative Research), Dementia Research, Dementia-Friendly Communities, Dementia-Friendly Design, Dementia-Friendly Products, Disease Modifying Treatment by 2025 (Aim), Disease-Modifying Therapies, Disease-Modifying Therapies for Dementia, Disproportionate Burden of Dementia on Women, Drug Discovery Programmes, Drug Identification, Drug Regulation, Drug-Development Pipeline, Emerging Leaders In Dementia (aka Young Leaders in Dementia), Experiences, First Global Ministerial Conference on Global Action Against Dementia, First WHO Ministerial Conference on Global Action Against Dementia, G7 Countries, G7 Dementia Summit, G7 Global Dementia Summit, G8 Dementia Summit, G8 Dementia Summit: Global Action Against Dementia, GAAD: Global Action Against Dementia, Global Action Against Dementia, Global Action Against Dementia (GAAD), Global Dementia Framework, Global Ministerial Conference on Global Action Against Dementia (WHO), Global Outlook, Global Toolbox for Dementia Research (Proposal), Government Research Funding, Group of 7 (G7), Home Care Standards, Intergenerational Cohesion, Intergenerational Mingling, Intergenerational Relations, Intergenerational Solidarity, Intergenerational Work, International Collaborations, International Dementia-Friendly Symbol (Proposal), International Programmes, Interventions: Outcomes and Cost Savings, Knowledge Translation, Leadership, Lived Experience, London, Mobile Technology, Multi-Generational Approaches, Multisectoral Collaboration, OECD, One-Stop Shops, Organisation for Economic Co-operation and Development (OECD), Organisation for Economic Co-operation and Development (OECD) Countries, Ottawa, Outcomes and Monitoring, Outcomes Benchmarking, Partnership, Partnership and Collaboration, Partnership Working, Patient Experience, Personal Experience of Dementia, Prevalence of Dementia, Prevention, Prevention Programmes, Prime Minister’s Dementia Challenge, Purple Angel Logo, Quality of Care, Quality of Care and Support, Quality of Care for People With Dementia, Reducing Stigma, Research and Development, Research and Innovation, Research Commitment, Research Funding, Science and Innovation Network (SIN), Service User Experience, Social Care Standards, Stigma, Stigma of Dementia, Stigma-Free Environments, Tokyo, UK Science and Innovation Network, UK Science and Innovation Network (SIN), Voluntary and SME Sectors, Washington DC, Working With Professionals From Other Sectors, World Health Organisation (WHO), World Health Organisation (WHO) Regional Office for Europe, Young Leaders in Dementia (#YLDementia), Young Leaders in Dementia (Canada Japan USA Europe), Young Leaders in Dementia Group
|
Leave a comment
Big Data Portal for Alzheimer’s Dementia Drug Discovery (NIH / Synapse AMP-AD)
Summary The National Institutes of Health (NIH) in the USA has opened a public-private partnership online resource to facilitate neurodegenerative research and drug development. The launch of the Alzheimer’s Big Data Portal provides an open-source “public knowledge portal” for the … Continue reading →
Posted in Charitable Bodies, For Doctors (mostly), For Researchers (mostly), In the News, International, Pharmacological Treatments, Quick Insights
|
Tagged Academia-Industry Partnerships, Academia-Industry Synergies, Accelerating Alzheimer's Research and Drug Development, Accelerating Medicine Partnership for Alzheimer's Disease (NIA-AMP AD) Target Discovery and Preclinical Validation Project, Accelerating Medicines Partnership (AMP), Accelerating Medicines Partnership-Alzheimer's Disease (AMP-AD), Alfred P. Sloan Foundation, Alzheimer’s Disease Biomarkers, Alzheimer’s Disease Cooperative Study, Alzheimer’s Disease Neuroimaging Initiative (ADNI), AMP-AD Program, Big Data, Big Data Portal for Alzheimer’s Dementia Drug Discovery, Big Pharma, Biomarkers, Biopharmaceutical Companies, Broad Institute of MIT and Harvard, Collaboration, Collaborative Drug Discovery Programmes, Collaborative Projects, Cross-Sector Partnerships, Dementia Research, Drug Development for Alzheimer's Disease, Drug Discovery Programmes, Drug Identification, Drug Target Validation, Drug-Development Pipeline, Drugs for Treatment of Alzheimer’s Disease, Emory University, Foundation for the NIH (FNIH), Genetic Research, Genetic Testing, Genetic Triggers, Genetics of Alzheimer's Disease, Global Open Data Initiative, Human Epigenome Atlas, Icahn School of Medicine at Mount Sinai, Institute for Systems Biology (Seattle), International Alzheimer's Disease Research Portfolio (IADRP), International Collaborations, International Organisations, International Programmes, Market Failure (Dementia Research and Drug Development), Mayo Clinic in Jacksonville, Medical Research, Multidisciplinary Research Teams, National Institutes of Health (NIH), Neurodegeneration, Neurodegenerative Disease Research, Neurodegenerative Diseases, NIA Genetics of Alzheimer’s Data Storage Site (NIAGADS), NIH Big Data to Knowledge (BD2K) Initiative, NIH Network for Excellence in Neuroscience Clinical Trials, Non-Profit Collaborations, Novel Targets in Neurodegeneration, Open Data, Open Data and Big Data, Open Data in Health and Social Care, Open Data Learning Capacity and Culture, Open Data: Unlocking Innovation, Open Source Solutions, Pharmaceutical Industry, Pharmacological Research, Potential of Open Data in Health and Social Care, Pre-Competitive Collaboration, Precision Medicine Initiative, Preclinical Biomarkers in Alzheimer's Disease, Public-Private Partnership (PPP), Public-Private Partnerships, Research and Development, Research and Innovation, Research Commitment, Research Consortia, Research Culture, Research Networks, Research Programmes, Roadmap Epigenomics Project, Rush University Medical Center: Chicago, Sage Bionetworks, Synapse, Synapse Access and Compliance Team, Target Discovery and Preclinical Validation, Technology Transfer, Temporal Evolution of Alzheimer’s Disease Biomarkers, Therapeutic Target(s): Identification, Translational Research, Transparency and Open Data, United States, University of California, University of Florida, US National Institute of Aging, US National Institutes of Health (NIH), USA
|
Leave a comment
Global Ministerial Conference on Global Action Against Dementia (WHO / Department of Health / Dementia Challenge)
Summary The World Health Organisation (WHO) will stage the First Global Ministerial Conference on Global Action Against Dementia on March 16th – 17th 2015, in Geneva. This event will engage a larger number of countries in the international focus on … Continue reading →
Posted in Acute Hospitals, Commissioning, Community Care, Dementia Care Pathway Group, Department of Health, Diagnosis, For Carers (mostly), For Doctors (mostly), For Nurses and Therapists (mostly), For Researchers (mostly), For Social Workers (mostly), In the News, Integrated Care, International, Management of Condition, Mental Health, Models of Dementia Care, Non-Pharmacological Treatments, Northern Ireland, Patient Care Pathway, Person-Centred Care, Pharmacological Treatments, Quick Insights, Standards, Statistics, UK, Universal Interest, World Health Organization (WHO)
|
Tagged Ageing and Dementia, Ageing and Society, Ageing Population, Awareness Raising, Burden of Dementia, Challenge on Dementia (David Cameron), Collaboration, Collaborative Projects, Cross-Sector Partnerships, Dementia Alliance International, Dementia Challenge, Dementia Diagnosis, Dementia Research, Department of Health's Digital Health Blog, Digital Engagement, Disease Modifying Treatment by 2025 (Aim), Disease-Modifying Therapies, Disease-Modifying Therapies for Dementia, Dr Margaret Chan: WHO Director-General, Drug Discovery Programmes, Drug Identification, Drug Regulation, Drug-Development Pipeline, First Global Ministerial Conference on Global Action Against Dementia, G8 Dementia Summit, G8 Dementia Summit: Global Action Against Dementia, Global Action Against Dementia, Global Ministerial Conference on Global Action Against Dementia (WHO), Global Outlook, Government Research Funding, Human Rights, International Collaborations, International Programmes, Kate Swaffer: Chair of Dementia Alliance International, Knowledge Translation, Leadership, OECD, Organisation for Economic Co-operation and Development (OECD), Organisation for Economic Co-operation and Development (OECD) Countries, Partnership, Partnership and Collaboration, Partnership Working, Prescribed Disengagement, Prevalence of Dementia, Prevention, Prevention Programmes, Prime Minister’s Dementia Challenge, Quality of Care, Quality of Care and Support, Quality of Care for People With Dementia, Reducing Stigma, Rehabilitation in Dementia, Research and Development, Research and Innovation, Research Commitment, Research Funding, World Health Organisation (WHO), World Health Organisation (WHO) Regional Office for Europe
|
Leave a comment
Global Clinical Trials Fund: GCTF (Alzheimer’s Research UK)
Summary Alzheimer’s Research UK has launched the Global Clinical Trials Fund (GCTF) to help finance trials which aim to translate discoveries in the lab into clinical treatments for the 830,000 people living with dementia in the UK. The GCTF aims … Continue reading →
Posted in Alzheimer’s Research UK, Charitable Bodies, For Doctors (mostly), For Nurses and Therapists (mostly), For Researchers (mostly), International, Management of Condition, Models of Dementia Care, National, Non-Pharmacological Treatments, Patient Care Pathway, Pharmacological Treatments, Quick Insights, Standards, UK, Universal Interest
|
Tagged Alzheimer’s Research UK Drug Discovery Institute, Clinical Research Networks, Clinical Trials, Clinical Trials (Phase I Through Phase III), Clinical Trials and Treatment Assessments, Collaboration, Collaborative Drug Discovery Programmes, Collaborative Projects, Commissioning Research, Dementia Consortium, Dementia Research, Dementia Research Priorities, Dementia Research: UK Impact, Disease Modifying Treatment by 2025 (Aim), Drug Discovery Institute, Drug Discovery Institutes, Drug Discovery Programmes, Drug Identification, Drug Target Validation, Drug Trials, Drug Trials Failure Rate, Drug-Development Pipeline, Drugs for Treatment of Alzheimer’s Disease, Experimental Alzheimer's Drugs, First G8 Dementia Summit, G8 Dementia Summit, GCTF: Global Clinical Trials Fund, Global Action Against Dementia, Global Clinical Trials Fund (GCTF), International Collaborations, International Organisations, International Programmes, Intervention Trials, Medical Research, Multidisciplinary Research Teams, Neurodegeneration, Neurodegenerative Disease Research, Neurodegenerative Diseases, New Drug Applications (NDAs), Non-Drug Intervention Trials, Novel Targets in Neurodegeneration, Pharmaceutical Industry, Pharmacological Research, Pharmacological Treatments, Pharmacotherapy, Pre-Competitive Collaboration, Research Commitment, Research Consortia, Research Culture, Research Programmes, Technology Transfer, Translational Research
|
Leave a comment